Skip to content

News

Genetic Testing Rates Found to be Low in Women With A Histo...

Genetic Testing Rates Found to be Low in Women With A History of Breast or Ovarian Cancer

(August 22, 2017) The Journal of Clinical Oncology recently published a study about the unmet need of genetic testing in women with breast and ovarian cancer. Women who fit eligibility criteria from the National Comprehensive Cancer Network (NCCN) took surveys focusing on discussions about genetic testing with a health professional, being advised to have genetic … Continued

FDA Approves New Indication and Formulation for Olaparib

FDA Approves New Indication and Formulation for Olaparib

(August 21, 2017) The US Food and Drug Administration (FDA) has granted full approval to olaparib tablets (Lynparza, AstraZeneca) for use as maintenance therapy for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have achieved a complete or partial response to platinum-based chemotherapy. This is not only a new indication for … Continued

Age When Giving Birth and Oral Contraceptives Influence One...

Age When Giving Birth and Oral Contraceptives Influence One’s Risk of Ovarian Cancer

(August 9, 2017) The International Journal of Cancer recently published an article on preliminary findings for two factors that influence one’s risk of ovarian cancer, namely the age at which a woman gives birth and the age at which she starts using oral contraceptives. The authors, including Celeste Leigh Pearce, PhD of OCRFA’s Scientific Advisory … Continued

Updated Patient Resources for Ovarian Cancer from the Natio...

Updated Patient Resources for Ovarian Cancer from the National Comprehensive Cancer Network

(July 31, 2017) The National Comprehensive Cancer Network (NCCN), has updated and published guidelines for patients with ovarian cancer. There are two parts to the resource guide: The Guidelines for Patients and Quick Guides. The NCCN Guidelines for Patients is an in depth look at topics such as testing, stages of cancer, and treatments. There … Continued

OCRFA Funded Project Has Breakthrough on Therapeutic Approa...

OCRFA Funded Project Has Breakthrough on Therapeutic Approach for Rare Ovarian Cancer

(July 27, 2017) Earlier this week, in Nature Cell Biology, researchers at The Wistar Institute published their findings about a few strategies to treat clear cell carcinoma. Clear cell is a rare form of ovarian cancer that does not usually respond well to platinum-based chemotherapy, which leaves patients with few options. In most cases of … Continued

Leading ovarian cancer organization announces 2017 honorees

Leading ovarian cancer organization announces 2017 honorees

Largest private funder of ovarian cancer research recognizes top researchers and community leaders NEW YORK — Today, Ovarian Cancer Research Alliance (OCRFA), the nation’s leading ovarian cancer research, advocacy and patient support organization, announces this year’s winners of its research and survivor awards at its annual conference. OCRFA honors two outstanding researchers for their cutting-edge … Continued

USPSTF Does Not Recommend Ovarian Cancer Screening for Gene...

USPSTF Does Not Recommend Ovarian Cancer Screening for General Population

(July 19, 2017) The United States Preventative Services Task Force (USPSTF) has once again recommended against screening for ovarian cancer in asymptomatic, average risk women. The draft statement, which was published on July 18th, does not apply to women who are positive for BRCA1 and BRCA2 genetic mutations, who have a higher risk of developing … Continued

Clinical Trial Shows Rucaparib Significantly Improved Progr...

Clinical Trial Shows Rucaparib Significantly Improved Progression-Free Survival in Ovarian Cancer Patients

(July 6, 2017) Clovis Oncology, Inc. recently announced topline data from the confirmatory phase 3 ARIEL3 trial of the drug rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied. Read the press release from Clovis Oncology.

Age-Specific Risk in Women with BRCA1 and BRCA2 Mutations

Age-Specific Risk in Women with BRCA1 and BRCA2 Mutations

(June 30, 2017) Ten thousand women, most of whom are BRCA1 or BRCA2 positive, were analyzed by the University of Cambridge in order to find age specific risk for breast and ovarian cancers. The goal of the study, which was published in the Journal of the American Medical Association (JAMA), was to better enable clinicians … Continued

Study Focused on Neuropathy in Female Cancer Survivors

Study Focused on Neuropathy in Female Cancer Survivors

(June 23, 2017) A clinical trial published in the Journal of Clinical Oncology focused on a largely understudied area of cancer survivorship: chemotherapy-induced peripheral neuropathy (CIPN) in women. Forty seven percent of the 512 women in the trial reported CIPN an average of 6 years after their treatment ended. Symptoms of CIPN reported during the … Continued

An Analysis on the Quality of Life in Long Term Survivors o...

An Analysis on the Quality of Life in Long Term Survivors of Advanced Stage Ovarian Cancer

(June 1, 2017) A study, published last month in Gynecologic Oncology, focused on an area of ovarian cancer that is rarely talked about: the quality of life (QOL) for long term survivors of advanced stage ovarian cancer. Woman surviving 8.5 years or longer, who had anywhere from 0 recurrences to multiple recurrences, were given surveys … Continued

The Risk of Blood Clots and Ovarian Cancer

The Risk of Blood Clots and Ovarian Cancer

(May 25, 2017) A retrospective study, published earlier this month in Obstetrics & Gynecology, looked at when women with ovarian cancer developed blood clots. One in four women diagnosed with ovarian cancer develop a blood clot, but more specifically, over eleven percent of those who developed a blood clot did so during neoadjuvant chemotherapy. Women … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.